Literature DB >> 31112988

The role of orexin-1 receptor signaling in demand for the opioid fentanyl.

Jennifer E Fragale1, Caroline B Pantazis1, Morgan H James1,2, Gary Aston-Jones3.   

Abstract

The orexin system is a potential treatment target for drug addiction. Orexin-1 receptor (OxR1) antagonism reduces demand for cocaine and remifentanil, indicating that orexin-based therapies may reduce demand for many classes of abused drugs. However, pharmacokinetics vary greatly among opioids and it is unclear if OxR1 antagonism would reduce demand for all opioids, particularly ones with high abuse liability. Here, we established a behavioral economics (BE) procedure to assess the effects of OxR1 antagonism on demand for the highly abused opioid fentanyl. We also investigated the utility of our procedure to predict OxR1 antagonism efficacy and relapse propensity. Demand parameters α (demand elasticity or price sensitivity of consumption, an inverse measure of drug motivation) and Qo (drug consumption at null cost) were assessed. The OxR1 antagonist SB-334867 (SB) decreased motivation (increased α) for fentanyl without affecting Qo. Baseline α values predicted SB efficacy, such that SB was most effective at reducing motivation (increasing α) in highly motivated rats. Baseline α values predicted the amount of cued reinstatement of fentanyl seeking; this reinstatement behavior was attenuated by SB administration. These results highlight the promise of the orexin system as a treatment target for opioid addiction and emphasize the usefulness of BE procedures in the study of opioid abuse.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31112988      PMCID: PMC6785092          DOI: 10.1038/s41386-019-0420-x

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  1 in total

1.  Use of the Exponential and Exponentiated Demand Equations to Assess the Behavioral Economics of Negative Reinforcement.

Authors:  Jennifer E C Fragale; Kevin D Beck; Kevin C H Pang
Journal:  Front Neurosci       Date:  2017-02-21       Impact factor: 4.677

  1 in total
  28 in total

1.  Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats.

Authors:  Alessandra Matzeu; Rémi Martin-Fardon
Journal:  Neuropharmacology       Date:  2019-12-04       Impact factor: 5.250

2.  Orexin-1 Receptor Signaling in Ventral Pallidum Regulates Motivation for the Opioid Remifentanil.

Authors:  Aida Mohammadkhani; Jennifer E Fragale; Caroline B Pantazis; Hannah E Bowrey; Morgan H James; Gary Aston-Jones
Journal:  J Neurosci       Date:  2019-10-22       Impact factor: 6.167

3.  Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?"

Authors:  Morgan H James; Gary Aston-Jones
Journal:  Brain Res       Date:  2020-01-10       Impact factor: 3.252

4.  Effects of 5-HT2A receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats.

Authors:  David Alexander Martin; Utsav Gyawali; Donna J Calu
Journal:  Addict Biol       Date:  2020-05-26       Impact factor: 4.280

5.  The orexin-1 receptor antagonist SB-334867 reduces motivation, but not inhibitory control, in a rat stop signal task.

Authors:  Joost Wiskerke; Morgan H James; Gary Aston-Jones
Journal:  Brain Res       Date:  2019-04-16       Impact factor: 3.252

Review 6.  The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse.

Authors:  Morgan H James; Jennifer E Fragale; Shayna L O'Connor; Benjamin A Zimmer; Gary Aston-Jones
Journal:  Neuropharmacology       Date:  2020-10-19       Impact factor: 5.250

7.  Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system.

Authors:  Jennifer E Fragale; Morgan H James; Gary Aston-Jones
Journal:  Addict Biol       Date:  2020-08-14       Impact factor: 4.280

8.  Changes in fentanyl demand following naltrexone, morphine, and buprenorphine in male rats.

Authors:  Lindsey R Hammerslag; Rebecca S Hofford; Qiwen Kang; Richard J Kryscio; Joshua S Beckmann; Michael T Bardo
Journal:  Drug Alcohol Depend       Date:  2019-12-16       Impact factor: 4.492

9.  Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil.

Authors:  Aida Mohammadkhani; Morgan H James; Caroline B Pantazis; Gary Aston-Jones
Journal:  Brain Res       Date:  2019-09-14       Impact factor: 3.252

Review 10.  Sleep dysregulation in binge eating disorder and "food addiction": the orexin (hypocretin) system as a potential neurobiological link.

Authors:  Jacqueline B Mehr; Deborah Mitchison; Hannah E Bowrey; Morgan H James
Journal:  Neuropsychopharmacology       Date:  2021-06-18       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.